GRI Bio, Inc. (GRI) · Nov 4, 2026 · Other events
546,529-share plan increase — 546,529 added shares; approximately 25% of 2.19M shares outstanding
GRI Bio’s annual meeting approved a major equity-plan expansion, extending awards through 2036 while increasing future dilution capacity.
GRI Bio is a clinical-stage biotech advancing GRI-0621 for idiopathic pulmonary fibrosis after Phase 2a data, while still needing substantial capital to move toward Phase 2b.
The main outcome is authorization for a materially larger equity-award pool. Stockholders approved adding 546,529 shares to the 2018 Equity Incentive Plan and extending its evergreen feature through January 1, 2036. 〔0〕 Against only 2.19 million shares outstanding, the increase is roughly 25% of the current share count—but these are potential future awards, not immediate share issuance.
That is useful for retaining a cash-constrained biotech workforce, but the trade-off is greater dilution capacity. The plan approval was already disclosed in the September 28, 2026 proxy and therefore was largely anticipated; the new information is that the proposal passed, not a change in the company’s clinical or financing trajectory.
The governance portion is routine and the filing does not show vote tallies. It confirms the director elections and plan approval, with 926,474 shares represented at the meeting, equal to approximately 42.37% of eligible shares. 〔1〕 Without FOR, AGAINST, and abstention counts, shareholder support cannot be judged beyond the fact of approval.
Bottom line: This clears a planned compensation authorization rather than advancing the drug pipeline. It modestly worsens the future dilution setup, but does not materially rewrite GRI Bio’s operating story today.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!